Table 1.
Socio-demographic and Clinical Characteristics and Physical Activity Levels among Non-Hispanic Black and White Breast Cancer Survivors
| TOTAL PHYSICAL ACTIVITY | |||||
|---|---|---|---|---|---|
| <60 minutes/week | 60 - <120 minutes/week | ≥ 120 minutes/week | P-valuea | ||
| N (%) | N (%) | N (%) | N (%) | ||
| Overall | 485 (100) | 231 (47.6) | 135 (27.8) | 119 (24.5) | 0.2 |
| Ageb | |||||
| <55 years | 182 (37.5) | 77 (42.3) | 57 (31.3) | 48 (26.4) | |
| 55 - <65 years | 158 (32.6) | 76 (48.1) | 47 (29.8) | 35 (22.2) | |
| ≥65 years | 145 (29.9) | 78 (53.8) | 31 (21.4) | 36 (24.8) | |
| Race | 0.01 | ||||
| Black | 136 (28.0) | 79 (58.1) | 32 (23.5) | 25 (18.4) | |
| White | 349 (72.0) | 152 (43.6) | 103 (29.5) | 94 (26.9) | |
| Marital Status | 0.05 | ||||
| Married/Living with Partner | 314 (64.9) | 137 (43.6) | 96 (30.6) | 81 (25.8) | |
| Divorced/Widowed / Single | 170 (35.1) | 94 (55.3) | 39 (22.9) | 37 (21.8) | |
| Educational Level | 0.01 | ||||
| ≤ High School | 61 (12.6) | 39 (63.9) | 8 (13.1) | 14 (23.0) | |
| ≥ Some college | 419 (86.4) | 192 (45.8) | 125 (29.8) | 102 (24.3) | |
| Employment Status | 0.03 | ||||
| Full-Time | 194 (40.2) | 85 (43.8) | 62 (32.0) | 47 (24.2) | |
| Part-Time | 85 (17.6) | 32 (37.7) | 31 (36.5) | 22 (25.9) | |
| Retired | 143 (29.7) | 77 (53.9) | 29 (20.3) | 37 (25.9) | |
| Otherc | 60 (12.4) | 36 (60.0) | 12 (20.0) | 12 (20.0) | |
| Income | 0.001 | ||||
| <$60,000 | 142 (29.3) | 85 (59.9) | 21 (14.8) | 36 (25.4) | |
| $60,000- <100,000 | 127 (26.2) | 61 (48.0) | 36 (28.4) | 30 (23.6) | |
| ≥$100,000 | 190 (39.2) | 73 (38.4) | 69 (36.3) | 48 (25.3) | |
| Unknownd | 26 (5.4) | 12 (46.2) | 9 (34.6) | 5 (19.2) | |
| Time since Diagnosis | 0.54 | ||||
| ≤ 1 year | 49 (10.1) | 23 (46.9) | 13 (26.5) | 13 (26.5) | |
| > 1 year | 384 (79.2) | 186 (49.6) | 109 (28.3) | 89 (22.1) | |
| Unknown | 52 (10.7) | 22 (42.3) | 13 (25.0) | 17 (32.7) | |
| Stage at Diagnosis | 0.67 | ||||
| Stage 0 | 14 (2.9) | 8 (57.1) | 4 (28.6) | 2 (14.3) | |
| Stage I | 235 (48.5) | 109 (46.4) | 65 (27.7) | 61 (26.0) | |
| Stage II | 114 (23.5) | 59 (51.8) | 32 (28.1) | 23 (20.2) | |
| Stage III/IV | 30 (6.2) | 17 (56.7) | 8 (26.7) | 5 (16.7) | |
| Missing/Unknown | 92 (19.0) | 38 (41.3) | 26 (28.3) | 28 (30.4) | |
| Her2 Status | 0.03 | ||||
| Unknown | 220 (45.4) | 96 (43.6) | 75 (34.1) | 49 (22.3) | |
| Negative | 205 (42.3) | 99 (48.3) | 49 (23.9) | 57 (27.8) | |
| Borderline | 41 (8.5) | 26 (63.4) | 9 (22.0) | 6 (14.6) | |
| Positive | 19 (3.9) | 10 (52.6) | 2 (10.5) | 7 (36.8) | |
| Time since AET initiation | 0.03 | ||||
| ≤ 6 months | 199 (41.0) | 101 (53.1) | 54 (27.0) | 44 (20.0) | |
| > 6 months | 221 (45.6) | 105 (47.5) | 54 (24.4) | 62 (28.1) | |
| Unknown | 65 (13.4) | 25 (38.5) | 27 (41.5) | 13 (20.0) | |
| AET Medication | 0.01 | ||||
| Aromatase Inhibitorg | 258 (56.0) | 151 (53.0) | 57 (32.4) | 50 (28.4) | |
| Tamoxifen | 203 (44.0) | 69 (39.2) | 68 (23.9) | 66 (23.2) | |
| Chemotherapy | 0.04 | ||||
| Yes | 120 (24.7) | 65 (54.2) | 23 (19.2) | 32 (26.7) | |
| No | 142 (29.3) | 64 (45.1) | 37 (26.1) | 41 (28.9) | |
| Unknown | 223 (46.0) | 102 (45.7) | 75 (33.6) | 46 (20.6) | |
| Radiation Treatment | 0.01 | ||||
| Yes | 214 (44.1) | 109 (50.9) | 48 (22.4) | 57 (26.6) | |
| No | 74 (15.3) | 41 (55.4) | 15 (20.3) | 18 (24.3) | |
| Unknown | 197 (40.6) | 81 (41.1) | 72 (36.6) | 44 (22.3) | |
| Surgery Typeh | 0.07 | ||||
| None/Unknown | 144 (29.7) | 59 (41.0) | 53 (36.8) | 32 (22.2) | |
| Lumpectomy | 189 (39.0) | 98 (51.9) | 43 (22.8) | 48 (25.4) | |
| Mastectomy | 152 (31.3) | 74 (48.7) | 39 (25.6) | 39 (25.6) | |
| Body Mass Index | <0.001 | ||||
| <25 kg/m2 | 162 (33.9) | 54 (33.3) | 55 (34.0) | 53 (33.7) | |
| 25 - <30 kg/m2 | 122 (25.5) | 62 (50.8) | 36 (29.5) | 24 (19.7) | |
| ≥30 kg/m2 | 194 (40.6) | 109 (56.2) | 44 (22.7) | 41 (21.1) | |
| Comorbidities | 0.0003 | ||||
| 1 | 24 (4.9) | 13 (54.2) | 5 (20.8) | 6 (25.0) | |
| > 1 | 219 (45.2) | 121 (57.3) | 41 (18.6) | 57 (24.1) | |
| Unknown | 242 (49.9) | 97 (40.1) | 89 (36.8) | 56 (23.1) | |
| Emotional/Informational Supporte | 0.84 | ||||
| ≤31 | 121 (24.9) | 60 (49.6) | 32 (26.5) | 29 (24.0) | |
| 32 – 39 | 243 (40.1) | 119 (49.0) | 66 (27.2) | 58 (23.9) | |
| >39 | 121 (24.9) | 52 (43.0) | 37 (30.6) | 32 (26.5) | |
| Tangible Support Scalef | 0.68 | ||||
| ≤15 | 130 (26.8) | 56 (43.1) | 40 (30.8) | 34 (26.2) | |
| 16 – 19 | 156 (32.2) | 73 (47.8) | 45 (28.9) | 38 (24.4) | |
| >19 | 199 (41.0) | 102 (51.3) | 50 (25.1) | 47 (23.6) | |
a
Wald X2 Test
b
Quartiles.
c
Full-time home-maker or family caregiver, unemployed, but seeking employment, student, other or refused to answer.
d
Respondent did not know or refused to answer.
e
Tertiles. Score range: 8 – 40. Higher score=better emotional support.
f
Tertiles. Score range: 4 – 20. Higher score=better tangible support.
g
Aromatase Inhibitors included: Anastrozole, Exemestane, Letrozole.
h
No surgery N=3; Missing/Unknown N=155; Mastectomy category includes women who reported having both a lumpectomy and mastectomy N=16